Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Stoppa

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Journal of Medical Genetics|September 5, 2006
The contribution of germline rearrangements to the spectrum of BRCA2 mutationsF Casilli, I Tournier, O M Sinilnikova, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
British Journal of Cancer|June 26, 2008
Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod, S Neuhausen, G Vichodez, et al.
Science (New York, N.Y.)|October 18, 2003
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1S Hacein-Bey-Abina, C Von Kalle, M Schmidt, et al.
Journal of the National Cancer Institute|August 13, 1998
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutationsS R Lakhani, J Jacquemier, J P Sloane, et al.
Nature Genetics|March 1, 1996
The complete BRCA2 gene and mutations in chromosome 13q-linked kindredsS V Tavtigian, J Simard, J Rommens, et al.
British Journal of Cancer|August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersO M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of Medical Genetics|September 5, 2006
The contribution of germline rearrangements to the spectrum of BRCA2 mutationsF Casilli, I Tournier, O M Sinilnikova, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classificationK Rahmani Narj Abadi, C Dupain, I Guillou, et al.
British Journal of Cancer|June 26, 2008
Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod, S Neuhausen, G Vichodez, et al.
Science (New York, N.Y.)|October 18, 2003
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1S Hacein-Bey-Abina, C Von Kalle, M Schmidt, et al.
Journal of the National Cancer Institute|August 13, 1998
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutationsS R Lakhani, J Jacquemier, J P Sloane, et al.
Nature Genetics|March 1, 1996
The complete BRCA2 gene and mutations in chromosome 13q-linked kindredsS V Tavtigian, J Simard, J Rommens, et al.
British Journal of Cancer|August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersO M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 10